Inactive Instrument

Oaktree Acquisition Corp. Stock Nyse

OAC.U

KYG671451212

Chart Oaktree Acquisition Corp.

Duration

Period

Style

Dynamic Chart

Latest news about Oaktree Acquisition Corp.

Jefferies Downgrades Hims & Hers Health to Hold From Buy, Cuts Price Target to $15 From $17	Apr. 16	MT
Canaccord Genuity Initiates Coverage on Hims & Hers Health With Buy Rating, $20 Price Target	Apr. 10	MT
Hims & Hers Appoints Christopher Payne as Newest Board Member	Apr. 03	CI
Hims & Hers Health Insider Sold Shares Worth $823,055, According to a Recent SEC Filing	Mar. 22	MT
Hims & Hers Health Insider Sold Shares Worth $965,016, According to a Recent SEC Filing	Mar. 15	MT
Hims & Hers Health Insider Sold Shares Worth $500,107, According to a Recent SEC Filing	Mar. 08	MT
Hims & Hers Health Insider Sold Shares Worth $685,288, According to a Recent SEC Filing	Mar. 05	MT
Hims & Hers Health Insider Sold Shares Worth $5,032,142, According to a Recent SEC Filing	Mar. 04	MT
Tigress Financial Boosts Price Target on Hims & Hers Health to $19 From $15, Cites Move to Accelerated Growth Phase, Keeps Buy Rating	Mar. 01	MT
Hims & Hers Health Shares Jump After Q4 Beat	Feb. 27	MT
Piper Sandler Adjusts Price Target on Hims & Hers Health to $11 From $9, Maintains Neutral Rating	Feb. 27	MT
Deutsche Bank Adjusts Hims & Hers Health Price Target to $14 From $8, Maintains Hold Rating	Feb. 27	MT
Truist Securities Adjusts Price Target on Hims & Hers Health to $13 From $10, Keeps Hold Rating	Feb. 27	MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Pre-Bell Tuesday; Hims & Hers Health Set to Gain, Intuitive Machines to Decline	Feb. 27	MT
Transcript : Hims & Hers Health, Inc., Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26

More news

Latest transcript on Oaktree Acquisition Corp.

Hims & Hers Health, Inc., Q4 2023 Earnings Call, Feb 26, 2024

Feb. 26

More transcripts

Analyst Recommendations on Oaktree Acquisition Corp.

Jefferies Downgrades Hims & Hers Health to Hold From Buy, Cuts Price Target to $15 From $17	Apr. 16	MT
Canaccord Genuity Initiates Coverage on Hims & Hers Health With Buy Rating, $20 Price Target	Apr. 10	MT
Hims & Hers Health Insider Sold Shares Worth $823,055, According to a Recent SEC Filing	Mar. 22	MT
Tigress Financial Boosts Price Target on Hims & Hers Health to $19 From $15, Cites Move to Accelerated Growth Phase, Keeps Buy Rating	Mar. 01	MT
Piper Sandler Adjusts Price Target on Hims & Hers Health to $11 From $9, Maintains Neutral Rating	Feb. 27	MT

More recommendations

Press releases Oaktree Acquisition Corp.

Hims & Hers to Announce First Quarter 2024 Financial Results on May 6, 2024	Apr. 15	BU
Hims & Hers Appoints Christopher Payne, Seasoned Tech Industry Executive, as Newest Board Member	Apr. 03	BU
Hims & Hers to Participate in Canaccord Genuity's Virtual eCommerce Sustainable Advantage Forum on March 14, 2024	Mar. 11	BU
Thinking about buying stock in Infobird, PubMatic, Hims & Hers Health, FibroGen, or Alpha Metallurgical Resources?	Feb. 27	PR
Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 26	BU

More press releases

News in other languages on Oaktree Acquisition Corp.

MÄRKTE USA/Uneinheitlich - Zurückhaltung vor Inflationsdaten	Feb. 27
MÄRKTE USA/Uneinheitlich - Zurückhaltung dominiert weiter	Feb. 27
MÄRKTE USA/Wall Street kommt wieder nicht vom Fleck	Feb. 27
MÄRKTE USA/Wall Street vor moderaten Aufschlägen	Feb. 27
MÄRKTE USA/Wall Street uneinheitlich - Anhaltende Zinssorgen	23-02-28

More news

Managers and Directors - Oaktree Acquisition Corp.

Managers	Age	Since
Oluyemi Okupe	57	-
Daniel Lieberman	-	-
Mike Chi	44	-

Members of the board	Age	Since
Delos Cosgrove	82	-
Ambar Bhattacharyya	41	-
Alex Bard	49	-

More insiders

Oaktree Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company focuses on identifying, acquiring and building a business in the industrial and consumer sectors.

Sector

Calendar

2024-05-05 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Sales 2024 *	1.19B	Sales 2025 *	1.47B	Capitalization	2.64B
Net income 2024 *	24M	Net income 2025 *	52M	EV / Sales 2024 *	2.03 x
Net cash position 2024 *	218M	Net cash position 2025 *	382M	EV / Sales 2025 *	1.54 x
P/E ratio 2024 *	162 x	P/E ratio 2025 *	55.1 x	Employees	-
Yield 2024 *	-	Yield 2025 *	-	Free-Float	0%